Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > CEA-Leti and Akrivis Technologies to Develop Nanomedicine Platform for High Payload Targeted Drug Delivery: New Theranostic Platform Will Combine Ultrasensitive Detection, High Payloads and More Efficient Cell Targeting

Abstract:
CEA-Leti and Akrivis Technologies, LLC announced their collaboration to develop an extremely adaptable, efficient and highly targeted drug delivery platform for chemotherapy and other treatments that require a high concentration of powerful drugs to be delivered precisely to targeted cells.

CEA-Leti and Akrivis Technologies to Develop Nanomedicine Platform for High Payload Targeted Drug Delivery: New Theranostic Platform Will Combine Ultrasensitive Detection, High Payloads and More Efficient Cell Targeting

Grenoble, France | Posted on June 19th, 2014

The new platform will be based on Akrivis Technologies' proprietary Z-TECT™ technology that targets and detects unusually low levels of proteins and molecular targets and Leti's Lipidot® nanovector delivery capability.

Developed by Akrivis Technologies, LLC, a biopharmaceutical company based in Cambridge, Mass. USA, Z-TECT™ is a unique technology platform that combines nanotechnology, molecular detection and immunology to provide high sensitivity and detection levels across multiple immunoassays and other assay formats, from colorimetric to fluorescent detection in vitro and imaging in vivo.

Developed by Leti and introduced for commercial uses in 2011, the Lipidot® technology is a versatile nano-delivery platform based on very small droplets of oil that encapsulate and carry drugs, fluorescent imaging agents or any other lipophilic payload to targeted cells for diagnosis or treatment.

By combining their delivery and targeting platforms, Leti and Akrivis intend to develop a new, more efficient and safer platform to deliver high payloads specifically to targeted cells. The resulting targeted nanoparticles will be optimized in a first phase for research and pre-clinical in vitro and in vivo applications. Then, in a second phase, they will be further developed clinically for in vitro diagnostics, in vivo imaging and targeted therapy.

"The new targeted nanoparticles jointly developed by Leti and Akrivis Technologies will dramatically improve the effectiveness of both diagnosis and treatment of diseases and reduce dangerous or unpleasant side effects," said Patrick Boisseau, head of Leti's nanomedicine program and chairman of the European Technology Platform - Nanomedicine (ETPN). "While specifically designed to meet the needs of pharmaceutical and biotech companies, the new platform will be customizable for other end-user applications such as diagnostics and theranostics."

"Detecting disease earlier and delivering the precise drug dosage at the right place at the right moment are major steps towards improving patient diagnosis and treatment as well as controlling healthcare costs," said Joel Berniac, CEO of Akrivis Technologies. "Akrivis and Leti have highly complementary nanomed technology platforms that will come together and offer physicians powerful new options for diagnosis and treatment."

Supported by AEPI, the Grenoble-Isère economic development agency, Akrivis Technologies and Leti created a joint lab, which was launched on June 2. "Leti's collaboration with Akrivis Technologies underscores Grenoble's strengths as a center for nanomedicine R&D and we are very pleased that they chose Leti and Grenoble for this exciting research and development project," said Joëlle Seux, AEPI director.

####

About CEA-Leti
By creating innovation and transferring it to industry, Leti is the bridge between basic research and production of micro- and nanotechnologies that improve the lives of people around the world. Backed by its portfolio of 2,200 patents, Leti partners with large industrials, SMEs and startups to tailor advanced solutions that strengthen their competitive positions. It has launched more than 50 startups. Its 8,000m² of new-generation cleanroom space feature 200mm and 300mm wafer processing of micro and nano solutions for applications ranging from space to smart devices. Leti’s staff of more than 1,700 includes 200 assignees from partner companies. Leti is based in Grenoble, France, and has offices in Silicon Valley, Calif., and Tokyo. Visit www.leti.fr for more information.

About Akrivis Technologies, LLC

Akrivis Technologies, LLC is a privately held biopharmaceutical company headquartered in Cambridge, Massachusetts, USA, committed to the early detection, diagnosis and treatment of serious and life-threatening diseases based on its patented Z-TECTTM technology platform. Unlike traditional methods, which are not readily adaptable across multiple assay formats and require special and expensive detection equipment, Akrivis’ Z-TECTTM technology platform amplifies signal at the source. It allows the detection in vitro of unusually low levels of proteins and molecular targets. Z-TECTTM is also capable of imaging millimeter-size lesions in animal models and will make clinical cancer detection in vivo possible at much lower levels of growth. Finally the same Z-TECTTM technology platform allows the delivery of high payloads of drug molecules specifically to targeted cells, offering exciting theranostic applications that can simultaneously combine diagnostic imaging with targeted therapy. Visit www.akrivis.com for more information.

For more information, please click here

Contacts:
CEA-Leti
+33 4 38-78-02-26


Akrivis
+1 617-827-2777


PR Agency
+33 6 64-52-81-10

Copyright © CEA-Leti

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Video captures bubble-blowing battery in action: Researchers propose how bubbles form, could lead to smaller lithium-air batteries April 26th, 2017

New Product Nanoparticle preparation from Intertronics with new Thinky NP-100 Nano Pulveriser April 26th, 2017

California Research Alliance by BASF establishes more than 25 research projects in three years April 26th, 2017

Affordable STM32 Cloud-Connectable Kit from STMicroelectronics Puts More Features On-Board for Fast and Flexible IoT-Device Development April 26th, 2017

Nanomedicine

New Product Nanoparticle preparation from Intertronics with new Thinky NP-100 Nano Pulveriser April 26th, 2017

Nanoparticle vaccine shows potential as immunotherapy to fight multiple cancer types April 24th, 2017

Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress(TM) April 20th, 2017

Nano-SPEARs gently measure electrical signals in small animals: Rice University's tiny needles simplify data gathering to probe diseases, test drugs April 17th, 2017

Announcements

Video captures bubble-blowing battery in action: Researchers propose how bubbles form, could lead to smaller lithium-air batteries April 26th, 2017

New Product Nanoparticle preparation from Intertronics with new Thinky NP-100 Nano Pulveriser April 26th, 2017

California Research Alliance by BASF establishes more than 25 research projects in three years April 26th, 2017

Affordable STM32 Cloud-Connectable Kit from STMicroelectronics Puts More Features On-Board for Fast and Flexible IoT-Device Development April 26th, 2017

Alliances/Trade associations/Partnerships/Distributorships

California Research Alliance by BASF establishes more than 25 research projects in three years April 26th, 2017

BASF and Landa partner to create revolutionary pigments for automotive coatings: The alliance combines BASF innovations with Landa nano-pigment technology April 5th, 2017

Leti Announces EU/South Korean Project for World’s First 5G-system Prototype: Coinciding with the 2018 Winter Games in PyeongChang, Korea, Prototype Will Be First Time State-of-the-art Terrestrial Wireless Communication Is Seamlessly Combined with Disruptive Satellite Communicati April 4th, 2017

ATTOPSEMI Technology Joins FDXcelerator Program to Deliver Advanced Non-Volatile Memory IP to GLOBALFOUNDRIES 22 FDX® Technology Platform: Leading-edge I-fuse™ brings higher reliability, smaller cell size and ease of programmability for consumer, automotive, and IoT applications March 27th, 2017

Research partnerships

California Research Alliance by BASF establishes more than 25 research projects in three years April 26th, 2017

Better living through pressure: Functional nanomaterials made easy April 19th, 2017

Shedding light on the absorption of light by titanium dioxide April 14th, 2017

AIM Photonics Presents Cutting-Edge Integrated Photonics Technology Developments to Packed House at OFC 2017, the Optical Networking and Communication Conference & Exhibition April 11th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project